Mesa Laboratories
MLAB
Market cap $530M

97.10 USD

-2.79

2.79%

At close Jun 13, 4:00 PM EDT

1 day

-2.79%

5 days

-8.74%

1 month

-23.51%

3 months

-20.62%

6 months

-23.88%

Year to date

-26.42%

1 year

4.41%

5 years

-57.17%

10 years

7.46%

About: Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in four divisions: Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables. The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Calibration Solutions division develops, manufactures, sells, and services quality control products.

Employees: 730

Technology Scientific & Technical Instruments

0

Funds holding %

of 7,296 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

1.17% more ownership

Funds ownership: 93.99% [Q4 2024] → 95.17% (+1.17%) [Q1 2025]

8% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 51

5% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 20

3% less funds holding

Funds holding: 156 [Q4 2024] → 151 (-5) [Q1 2025]

9% less capital invested

Capital invested by funds: $673M [Q4 2024] → $613M (-$59.8M) [Q1 2025]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$100

3%

upside

Avg. target

$100

3%

upside

High target

$100

3%

upside

1 analyst rating

0 positive

0%

0 neutral

0%

1 negative

100%

Wells Fargo

Brandon Couillard

3%upside

$100

Underweight

Maintained

30 May 2025

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

Mesa Labs (MLAB) Q4 Earnings and Revenues Lag Estimates

Mesa Labs (MLAB) came out with quarterly earnings of $2.23 per share, missing the Zacks Consensus Estimate of $2.75 per share. This compares to earnings of $2.77 per share a year ago.

Mesa Labs (MLAB) Q4 Earnings and Revenues Lag Estimates

Mesa Labs Announces Fourth Quarter and Full Fiscal Year 2025 Results

LAKEWOOD, Colo., May 28, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its fourth fiscal quarter (“4Q25”) and full fiscal year (“FY25”) ended March 31, 2025 (amounts in thousands).

Mesa Labs Announces Fourth Quarter and Full Fiscal Year 2025 Results

MESA LABS DECLARES QUARTERLY DIVIDEND

LAKEWOOD, Colo., April 07, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 16, 2025, to shareholders of record at the close of business on May 30, 2025.

MESA LABS DECLARES QUARTERLY DIVIDEND

Investors Business Daily

How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain

Tariff uncertainty has cast a pall over medical stocks. Re-shoring is possible, but expensive, leaving them in a "wait-and-see" pattern.

How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain

Zacks Investment Research

What Makes Mesa Labs (MLAB) a New Strong Buy Stock

Mesa Labs (MLAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

What Makes Mesa Labs (MLAB) a New Strong Buy Stock

Zacks Investment Research

Why Mesa Labs (MLAB) Might be Well Poised for a Surge

Mesa Labs (MLAB) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Why Mesa Labs (MLAB) Might be Well Poised for a Surge

Zacks Investment Research

Mesa Labs (MLAB) Q3 Earnings and Revenues Beat Estimates

Mesa Labs (MLAB) came out with quarterly earnings of $2.67 per share, beating the Zacks Consensus Estimate of $2.45 per share. This compares to earnings of $2.02 per share a year ago.

Mesa Labs (MLAB) Q3 Earnings and Revenues Beat Estimates

Mesa Labs Announces Third Quarter Results

LAKEWOOD, Colo., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its third fiscal quarter (“3Q25”) ended December 31, 2024 (amounts in thousands).

Mesa Labs Announces Third Quarter Results

Mesa Laboratories, Inc. to Announce Third Quarter Results on February 4, 2025

LAKEWOOD, Colo., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the third quarter of fiscal year 2025 at approximately 8:00 A.M. Eastern time on Tuesday, February 4, 2025.

Mesa Laboratories, Inc. to Announce Third Quarter Results on February 4, 2025

MESA LABS DECLARES QUARTERLY DIVIDEND

LAKEWOOD, Colo., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 17, 2025, to shareholders of record at the close of business on February 28, 2025.

MESA LABS DECLARES QUARTERLY DIVIDEND

See News Rankings

Charts implemented using Lightweight Charts™